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Abstract
Background: Cell therapy with bone marrow (BM)-derived progenitors has emerged as a promising therapeutic for
refractory angina (RA) patients. In the present study, we evaluated the safety and preliminary efficacy of transcatheter
delivery of autologous BM-derived advanced therapy medicinal product CD133+ cells (ATMP-CD133) in RA patients,
correlating perfusion outcome with cell function.
Methods: In the phase I “Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory
Cardiomyopathy” (RECARDIO) trial, a total of 10 patients with left ventricular (LV) dysfunction (ejection fraction
≤ 45%) and evidence of reversible ischemia, as assessed by single-photon emission computed tomography
(SPECT), underwent BM aspiration and fluoroscopy-based percutaneous endomyocardial delivery of ATMP-CD133.
Patients were evaluated at 6 and 12 months for safety and preliminary efficacy endpoints. ATMP-CD133 samples were
used for in vitro correlations.
Results: Patients were treated safely with a mean number of 6.57 ± 3.45 × 106 ATMP-CD133. At 6-month follow-up,
myocardial perfusion at SPECT was significantly ameliorated in terms of changes in summed stress (from 18.2 ± 8.6 to
13.8 ± 7.8, p = 0.05) and difference scores (from 12.0 ± 5.3 to 6.1 ± 4.0, p = 0.02) and number of segments with inducible
ischemia (from 7.3 ± 2.2 to 4.0 ± 2.7, p = 0.003). Similarly, Canadian Cardiovascular Society and New York Heart
Association classes significantly improved at follow-up vs baseline (p ≤ 0.001 and p = 0.007, respectively). Changes
in summed stress score changes positively correlated with ATMP-CD133 release of proangiogenic cytokines HGF
and PDGF-bb (r = 0.80, p = 0.009 and r = 0.77, p = 0.01, respectively) and negatively with the proinflammatory cytokines
RANTES (r = − 0.79, p = 0.01) and IL-6 (r = − 0.76, p = 0.02).
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Conclusion: Results of the RECARDIO trial suggested safety and efficacy in terms of clinical and perfusion outcomes in
patients with RA and LV dysfunction. The observed link between myocardial perfusion improvements and
ATMP-CD133 secretome may represent a proof of concept for further mechanistic investigations.
Trial registration: ClinicalTrials.gov, NCT02059681. Registered 11 February 2014.
Background
Continual technical improvements in mechanical coronary
revascularization have produced as a paradoxical effect a
growing number of patients with severe coronary disease,
which are no more suitable for further revascularizations
and experience refractory angina (RA) despite best medical
management. It has been estimated that RA approximates
an incidence as high as 50,000 and 30,000–50,000 new
cases per year in the USA and continental Europe, respect-
ively [1, 2]. Although the mortality prognosis has improved
over time, with current rates approaching 3–5% per year
[3, 4], the morbidity counterpart of such a challenging con-
dition still remains a relevant burden for patients as well as
health care systems. In particular, RA patients complain of
inadequate pain relief leading to revisits to local hospital
emergency departments, and undergo repeated coronary
investigations [5]. The presence of left ventricular (LV) dys-
function worsens this scenario, contributing to reduce
long-term survival and to increase hospitalization rates [2].
In this context, it has been unambiguously shown that is-
chemia reduction has a pivotal importance for patient sur-
vival [6]. Available treatment options on top of best
interventional and medical therapy are still limited. En-
hanced external counterpulsation, shock waves and coron-
ary sinus reduction [7, 8] have shown therapeutic potential,
although none of them has so far gained enough accept-
ance to enter the routine therapeutic armamentarium.
Cell therapy (CT) with autologous bone marrow
(BM)-derived or peripheral blood (PB)-derived vasculo-
genic cells has emerged as an alternative viable thera-
peutic option [9, 10]. Randomized controlled trials
(RCT) as well as meta-analyses and pooled analyses have
recognizably shown, in large cohorts of RA patients, that
catheter-based intramyocardial injection of BM or
PB-derived selected or unselected progenitors has the
ability to improve symptoms, exercise capability and
myocardial perfusion with durable effects [11–13].
Nevertheless, in order to gain widespread acceptance and
reimbursement from health care systems, pivotal studies as
well as large RCT better addressing the cell mode of action
(MoA) are still awaited [14]. Moreover, the priority issue
about safety and efficacy in the subset of RA patients with
LV dysfunction remains to be confirmed, for which less in-
formation is available in the literature.
Our group has pioneered the feasibility and safety of
direct intramyocardial delivery of BM-derived CD133+
progenitors when injected epicardially through a minim-
ally invasive approach in the context of a “no-option”
RA population [15]. Furthermore, we validated the good
manufacturing practice (GMP)-compliant standard op-
erative procedures (SOP) required to translate human
BM-derived CD133+ cells as an autologous advanced
therapy medicinal product (ATMP-CD133) in the car-
diovascular scenario [16, 17].
We here report 1-year safety and preliminary efficacy re-
sults of the transcatheter intramyocardial injection of
ATMP-CD133 in RA patients with LV dysfunction and
concomitant heart failure (HF) and the correlation with
myocardial perfusion outcome with CD133+ cell function.
Methods
Study design
The “Endocavitary Injection of Bone Marrow Derived
CD133+ Cells in Ischemic Refractory Cardiomyopathy”
(RECARDIO) trial is a prospective, multicenter, unblinded,
phase I clinical study (ClinicalTrials.gov NCT02059681).
The trial was performed at two investigational sites: Centro
Cardiologico Monzino-IRCCS (Milan, Italy) as the coordin-
ating and recruiting center, and Città della Salute e della
Scienza Hospital (Turin, Italy) as the recruiting center. The
institutional review board at each center approved the
protocol and all patients gave informed consent prior to
participation. Patients were excluded in the case of de-
nial and might withdraw from the study at any time,
irrespective of the reason. The study complied with
the Declaration of Helsinki and was approved by the
local ethical committees (CCFM225/612 and CS/154)
and the Italian Competent Authority (Istituto Super-
iore di Sanità, 15,934(13)PRE21-1199).
The study design comprised a screening phase in
which patients were checked for inclusion/exclusion cri-
teria and post-procedure follow-up visits scheduled at 6
and 12 months, as safety and efficacy endpoints (Fig. 1).
Specifically, the baseline screening assessment was per-
formed within 2 months before the injection procedure
and included: clinical evaluation as Canadian Cardiovas-
cular Society (CCS) and New York Heart Association
(NYHA) classes, concomitant medications, patients’
quality of life and health status; single photon emission
computed tomography (SPECT); cardiopulmonary exercise
testing (CPET); two-dimensional (2D) echocardiogram; car-
diac magnetic resonance (CMR) when applicable; Holter
ECG monitoring; and blood tests. The patients’ quality of
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life and health status were evaluated using the Short
Form-12 (SF-12) survey and the Minnesota Living with
Heart Failure Questionnaire (MLHFQ). In particular, the
SF-12 survey consists of two parts—the Physical Compo-
nent Summary (PCS) and the Mental Component Sum-
mary (MCS)—while the MLHFQ is a 21-question tool to
test patients’ perception of the impact of HF.
At 6 and 12 months, clinical evaluation, 2D echocar-
diogram and blood tests were repeated. Moreover,
SPECT and CPET were also evaluated at 6 months. Ad-
verse events (AE), serious adverse events (SAE) and
major adverse cardiac events (MACE) were continuously
evaluated up to 12 months.
Study population
The study population consisted of patients with severe
CCS angina class III–IV and/or NYHA score II–IV
under maximal tolerated medical therapy for at least
3 months not eligible for any type of conventional
mechanical revascularization procedure based on the
most recent coronary angiography (≤ 12 months). Add-
itional inclusion criteria were: LV ejection fraction (EF) ≤
45% as determined by 2D echocardiogram, CMR, or left
ventriculogram; a reversible perfusion defect ≥ 10% of
the LV surface by SPECT; and peak oxygen consumption
(VO2) ≤ 21 ml/kg/min at CPET. Major exclusion criteria
included: myocardial infarction (MI) within 3 months; pres-
ence of LV thrombus; LV wall thickness < 8 mm at the target
area of cell injections as assessed by 2D echocardiogram;
mechanical aortic valve; severe renal failure (creatinine
plasma level > 2.5 mg/dl); positive infectious-disease test for
HIV, hepatitis B or C, Treponema pallidum, human T-cell
lymphotropic virus 1 and 2; and history of malignancy in
the past 5 years.
Study endpoints
The primary aim of the study was safety in terms of any
treatment-emergent SAE documented up to 6 months
post catheterization and defined as cardiac perforation,
pericardial tamponade, sustained ventricular tachycar-
dia/fibrillation and ectopic tissue formation. Additional
safety endpoints were evaluated up to 12 months post
procedure and included any AE, SAE and MACE de-
fined as composite of death, nonfatal MI, stroke and
hospitalization for worsening of HF.
The secondary aim was the efficacy of the procedure
in terms of improvements of LV perfusion at SPECT
and/or functional capacity as assessed by CPET at
6 months postoperatively.
The third aim was to correlate perfusion and func-
tional benefits with in vitro angiogenic potency of
injected cells in terms of endothelial differentiation, col-
ony forming unit capacity and cytokine production.
Cell preparation
Approximately 350 ml of BM was aspirated from the
posterior iliac crest under epidural anesthesia according
to the anesthesiologist’s judgment. The procedures were
performed by an experienced hematologist within a
qualified operating room. BM blood samples were antic-
oagulated with sodium heparin 5000 UI, stored in bags
and shipped at controlled temperature (+ 4 °C/+ 20 °C)
to the GMP-qualified facility (Cell and Gene Therapy
Laboratory “Stefano Verri”, Monza, Italy).
Since 2007, the Laboratory has been cleared by the
Italian Medicines Agency (Agenzia Italiana del Farmaco
(AIFA)) for the manufacturing of ATMPs (current
authorization aM-185 2017), including ATMP-CD133.
The manufacturing, quality control and transport pro-
cesses were performed and documented in agreement
with validated SOP and GMP requirements.
Each lot was released if the following specifications
were met: cellularity 1–12 × 106 CD133+ cells; purity (%
Fig. 1 Study flow chart. SPECT gated-single photon emission
computed tomography, CPET cardiopulmonary exercise testing,
CMR cardiac magnetic resonance, 2D two-dimensional, ECG
electrocardiogram, ATMP advanced therapy medicinal product,
AE adverse event, SAE serious adverse event, MACE major
adverse cardiac events
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of CD133+ cells/CD45+ cells) ≥ 80%; vitality ≥ 80%;
endotoxin < 0.5 EU/ml; and sterile. Cells were stored
overnight, resuspended in 10 ml of physiological saline,
aliquoted in a sterile polypropylene conical tube and
packed by the manufacturer as a “ready-to-use” cell
product. Based on our stability data [17], cell suspen-
sions were administered within 24 h from the lot release.
Cell administration and postprocedure monitoring
The day following BM aspiration, patients were admitted
to the catheterization laboratory to receive the
fluoroscopy-based transendocardial cell injections. The
injection technique was performed as previously described
[18]. Briefly, selection of target injection sites was done by
merging coronary angiography, SPECT and 2D echocar-
diogram imaging. Upon retrograde LV catheterization,
two-view ventriculography was performed to trace LV
chamber end-diastolic/end-systolic profiles and
color-mark the target landing zone; the different sites for
infusion were subsequently chosen within this area. To
better guide the Helical Infusion Catheter (BioCardia
Inc.), real-time intracardiac echocardiography (ICE) was
used in all cases to monitor the appropriate intramyocar-
dial location of the needle during cell delivery and to ex-
clude the release of microbubbles into the cavity.
Furthermore, ICE was able to directly visualize the cardiac
structures (such as valves and ventricle papillary muscles)
and promptly detect procedural complications (such as
thrombus formation, valve damage, pericardial effusion,
cardiac tamponade). In selected cases, 3D electroanatomi-
cal mapping (CARTO; BiosenseWebster) was obtained in
the area of interest to validate tissue viability by electro-
gram analysis at the site of injections [19].
The 10 ml total volume was delivered by means of a
range of 11–13 injections by slow infusion of 0.5–0.7 ml
from the aliquot syringes over 30 s. At the end of the in-
jection procedure, an implantable loop recorder (ILR)
was subcutaneously inserted in the upper chest area to
provide 12-month continuous arrhythmia monitoring.
To rule out cardiac tamponade or other cardiac-related
complications, all patients underwent a postprocedure 2D
echocardiogram and then were monitored overnight by
telemetry and measuring vital signs in the intensive care
unit.
Patients were hospitalized for a minimum of 48 h after
the procedure. Before discharge, 2D echocardiogram,
24-h ECG Holter monitoring, standard chest X-ray im-
aging and routine blood tests were checked.
Myocardial perfusion analysis
SPECT perfusion studies were performed at baseline
and 6 months after the procedure to evaluate the pres-
ence and the extent of reversible ischemia, expressed as
a percentage of the LV. Stress and rest SPECT images
were acquired 15–60 min after the injection of 555 MBq
99mTc-Tetrofosmin. ECG-SPECT images were performed
with patients in the supine position for a total of 64 pro-
jections, 3° interval, every 30 s, over a 180° elliptical
orbit. Pharmacological stress with intravenous adminis-
tration of dipyridamole (0.84 mg/kg over 6 min) or rega-
denoson (0.4 mg/5 ml) was used to obtain stress images.
Both stress and rest acquisitions were obtained using a
dual-head digital camera at 90° geometry equipped with
high-resolution collimators. LVEF and volumes were cal-
culated using a completely automated algorithm, previ-
ously described and validated [20].
The gated images were normalized to the region of
highest activity on the end-systolic image set. Regional
myocardial perfusion was assessed on the summed im-
ages. Perfusion imaging was scored semi-quantitatively
using a 20-segment model scored on a 5-point scale (0 =
normal, 4 = no uptake) [21]. A perfusion defect with a
score ≥ 3 was considered significant, and a segment score
improved by at least one grade was considered reversible.
The summed stress score (SSS) and summed rest score
(SRS) were calculated in each patient by adding the 20 in-
dividual perfusion scores. The difference between the
summed stress and rest scores is the summed difference
score (SDS), which indicated the amount and the degree
of reversible ischemia. The paired SPECT images were
evaluated by two independent imaging readers blinded to
the clinical data.
Echocardiographic and functional capacity assessments
A 2D echocardiogram was performed at baseline, before
hospital discharge and after 6 and 12 months to evaluate
LV function, volumes and wall motion score index (WMSI).
Pericardial effusions and unwanted tissue changes were also
assessed during the study period. Echocardiogram acquisi-
tion and analyses were performed according to the guide-
lines [22]. The 2D echocardiogram at screening was also
applied to assess the presence and localization of LV wall
thickness < 8 mm at the target sites of cell injections.
CPET studies were performed at baseline and 6 months
postoperatively to assess changes in functional capacity.
CPET were performed on a cycle ergometer using an in-
cremental ramp protocol. Expiratory O2, CO2 and venti-
lation were measured breath by breath. Patients were
encouraged to perform as maximal exercise as possible.
Peak VO2 was reported as a mean over the last 20 s of
exercise.
ATMP-CD133 in vitro analyses
A small amount of each ATMP-CD133 lot was obtained
from the GMP facility to perform in vitro studies. The
experimental plan is shown in Fig. 2.
In detail, samples were thawed and seeded at 105 cells/
well in 96-well plates in StemSpan (STEMCELL
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Technologies) supplemented with interleukin (IL)-3 and
IL-6 (both at 20 ng/ml; Peprotech), flt3 ligand (FLT3LG)
and stem cell factor (SCF) (both at 100 ng/ml; Pepro-
tech) to allow cell proliferation. The ATMP-CD133
growing capacity was assessed using the cumulative
population doubling levels (CPDL), as previously
described [23].
After three expansion passages, samples were seeded
onto Fibronectin (Sigma-Aldrich)-coated dishes in M199
medium (Gibco) supplemented with 20% fetal bovine
serum (FBS; Microtech), 2 mM L-glutamine (Euroclone)
and 100 U/ml penicillin/streptomycin. Seeded cells were
cultured for 2, 7 or 14 days to carry out the secretome
and the flow cytometry analyses, to measure the produc-
tion of colony forming unit-endothelial cells (CFU-EC)
and to assess the immunophenotype of cultured cells. In
particular, after 2 days, ATMP-CD133 secretome
(expressed as pg/ml/105 cells) was characterized using
a customized Bio-Plex assay (BIO-RAD). The panel
comprised six proangiogenic factors including SCF,
growth-regulated oncogene alpha (GRO-α), vascular
endothelial growth factor (VEGF), platelet-derived
growth factor type bb (PDGF-bb), hepatocyte growth
factor (HGF) and IL-8; four proinflammatory factors
including monocyte chemoattractant protein-1 (MCP-1),
macrophage inflammatory protein-1 beta (MIP-1β), regu-
lated on activation normal T cell expressed and secreted
(RANTES) and IL-6; and two anti-angiogenic factors in-
cluding leukemia inhibitory factor (LIF) and IL-10. As a
negative control, nonconditioned medium was tested.
Immunophenotype analysis of endothelial markers
(CD31, KDR, CD144) [24] was performed by multicolor
flow cytometry on cultured cells after 7 and 14 days of
endothelial conditioning. After detachment, using a non-
enzymatic method, cells were resuspended in washing
buffer (WB) containing PBS, 0.1% BSA (Gibco) and
2 mM EDTA (Gibco), and incubated in the dark for
15 min with suitable combinations of the following
monoclonal or isotype-matched control antibodies:
CD31-FITC (clone WM59; BD), KDR-PE (clone 89,106;
R&D Systems) and CD144-APC (clone 16B1; R&D Sys-
tems). Then, samples were washed with 1 ml of WB and
Fig. 2 Schematic representation of the in vitro experimental plan. GMP good manufacturing practice, ATMP advanced therapy medicinal product,
IL interleukin, SCF stem cell factor, FBS fetal bovine serum, PDGF-bb platelet-derived growth factor type bb, GRO-α growth-regulated oncogene
alpha, HGF hepatocyte growth factor, VEGF vascular endothelial growth factor, RANTES regulated on activation normal T cell expressed and
secreted, MIP-1b macrophage inflammatory protein-1 beta, MCP-1 monocyte chemoattractant protein-1, LIF leukemia inhibitory factor,
FACS fluorescence-activated cell sorting, CFU-EC colony forming unit-endothelial cell, Ac-LDL-Dil acetylated low-density lipoprotein labeled
with dioctadecyl-tetramethylindocarbocyanine perchlorate, UEA-1 Ulex europaeus agglutinin-1
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centrifuged for 10 min at 400 × g at 4 °C to remove un-
bound antibodies. Cells were then resuspended in 250 μl
of WB and analyzed with a Gallios™ Flow Cytometer
(Beckman Coulter).
After 14 days in differentiation-promoting conditions,
a CFU-EC assay was performed as previously described
[16]. For immunofluorescence analysis, cells were in-
cubated in the dark for 5 h at 37 °C with 10 μg/ml
of acetylated low-density lipoprotein labeled with
dioctadecyl-tetramethylindocarbocyanine perchlorate
(Ac-LDL-Dil; Biomedical Technologies). After washing
with PBS, cells were fixed with 4% paraformaldehyde
(Sigma-Aldrich) for 20 min and then stained with
40 μg/ml of FITC-labeled Lectin from Ulex europaeus
agglutinin-1 (UEA-1 Lectin; Sigma-Aldrich) in the dark
for 1 h. Nuclei were stained with Hoechst 333,428
(Sigma-Aldrich) in the dark for 15 min. Cells were ob-
served with a Zeiss LSM 710 confocal microscope.
Statistical analyses
Continuous variables were expressed as mean ± SD or
median (interquartile range (IQR)), as appropriate. A
within-subject Student’s t test was used to compare
baseline and 6-month follow-up data. To evaluate differ-
ences in the distribution of continuous data at baseline,
6-month and 12-month follow-up, one-way ANOVA or
the Friedman test for repeated measures were performed
with Bonferroni or Dunn’s post-hoc analysis, respect-
ively. Correlations between continuous variables were
assessed by Pearson or Spearman test, as appropriate.
All tests were two-tailed, with a statistically significant
p ≤ 0.05. All of the analyses were performed with Graph-
Pad Prism® software (version 5.0).
Results
Patient characteristics
Between December 2013 and November 2016, 10 consecu-
tive patients were enrolled and followed up for a period of
12 months according to the study protocol. Baseline char-
acteristics are presented in Table 1. All patients were males
and the mean age was 69.4 ± 3.8 years. All patients had a
history of coronary artery bypass grafting and seven pa-
tients experienced MI. Two patients were implantable car-
dioverter defibrillator (ICD) recipients and two patients had
a spinal cord stimulator. Medications at baseline, including
the use of long-lasting nitroglycerin and ranolazine to man-
age RA, are presented in Table 1.
BM harvesting and ATMP-CD133 lot release
A mean 349 ± 57 ml of BM was aspirated under epidural
anesthesia in the absence of adverse events. The mean
procedural time was 24 ± 10 min.
At the end of the GMP manufacturing process, the
mean number of ATMP-CD133 was 6.57 ± 3.45 × 106
cells. The median (IQR) cell purity and vitality was
88.77% (86.30–90.75%) and 99.90% (99.85–99.95%), re-
spectively (Table 2).
Transendocardial delivery of ATMP-CD133
Fluoroscopy-guided endocavitary intramyocardial cell
injections were successfully accomplished in all 10
patients. Patients received a mean total volume of 7.76 ±
0.8 ml, delivered in a median of 12 independent injections
of 0.5–0.7 ml each. All injections were double-checked
with ICE to confirm engagement of the needle into
Table 1 Patients’ characteristics
Characteristic Baseline
Age (years), mean ± SD 69.4 ± 3.8
Males, n/total 10/10
BMI (kg/m2), mean ± SD 26.3 ± 2.4
Cardiovascular risk factors, n/total
Current smoking 7/10
Diabetes mellitus 6/10
Hypertension 10/10
Hypercholesterolemia 9/10
Family history of CAD 6/10
Medical history, n/total
Prior CABG 10/10
Prior MI 7/10
Prior PCI 8/10
Prior ICD implant 2/10
Spinal cord stimulation 2/10
Peripheral vascular disease 1/10
Current medications, n/total
β-Blockers 9/10
ACE inhibitors 5/10
ARBs 3/10
Calcium antagonists 1/10
Diuretics 6/10
Statins 10/10
Aspirin 8/10
Ranolazine 7/10
Long-lasting nitroglycerin 6/10
Cardiovascular condition at enrolment, mean ± SD
LVEF (%) 38.3 ± 5.1
LV reversible ischemia (%) 15.3 ± 8.4
Peak VO2 (ml/kg/min) 13.3 ± 1.8
Continuous data presented as mean ± SD
SD standard deviation, BMI body mass index, CAD coronary artery disease,
CABG coronary artery bypass grafting, MI myocardial infarction, PCI percutaneous
coronary intervention, ICD implantable cardioverter defibrillator, ACE
angiotensin converting enzyme, ARB angiotensin II receptor blocker, LVEF left
ventricular ejection fraction, LV left ventricle, VO2 oxygen consumption
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the LV wall. Mean total procedural duration was
252 ± 91 min, while the mapping and injection time
averaged 105 ± 29 min (Table 2). In four cases, the injec-
tion procedure was preceded by CARTO-guided electroa-
natomical mapping. An ILR was implanted in eight
patients, with the exception of two cases who were already
recipients of an ICD.
Safety profile of ATMP-CD133
There were no treatment-emergent in-hospital SAE re-
lated to the transendocardial delivery of ATMP-CD133.
In 3 out of 10 patients, mild to moderate (≤ 15 mm)
pericardial effusions were recorded on 2D echocardio-
gram during the 24 h postoperative monitoring. These
events were all spontaneously resolved before hospital
discharge. During the 12-month arrhythmia follow-up,
no patient presented episodes of sustained ventricular
tachycardia or ventricular fibrillation as documented by
ILR or ICD continuous monitoring.
No patient died during the 1-year safety follow-up.
Two MACE and six nonprocedure-related SAE
occurred during the 12-month study period. As for
MACE, two patients experienced nonfatal non-ST ele-
vation MI at 8 and 12 months, respectively, after the
injection procedure. The first patient received PCI of
the right coronary artery in territories distal from the
targeted injection area and the second was managed
conservatively based on coronary angiography. Two
patients were treated with ICD implantation in pri-
mary prevention 6 months after the cell treatment.
One patient reported two SAE during the follow-up,
requiring emergency room admission for epigastric
ulcer and subdural hematoma after 2 and 8 months,
respectively. Finally, one patient, with known periph-
eral vascular disease, underwent elective percutaneous
angioplasty of the femoral superficial artery 5 months
after the procedure.
Perfusion outcome
Follow-up SPECT was available in 9 out of 10 patients.
Myocardial perfusion was significantly ameliorated at
6 months compared with baseline. In particular, the SSS
improved from 18.2 ± 8.6 to 13.8 ± 7.8 (p = 0.05; Fig. 3a)
while the SRS did not change significantly (5.9 ± 5.2 vs
7.3 ± 7.9, p = 0.38; Fig. 3b). Moreover, the SDS decreased
from 12.0 ± 5.3 to 6.1 ± 4.0 (p = 0.02; Fig. 3c). As for is-
chemic myocardial segments, a highly significant differ-
ence was found in the number of segments showing
inducible myocardial ischemia (from 7.3 ± 2.2 to 4.0 ± 2.7,
p = 0.003; Fig. 3d).
Echocardiographic and functional outcome
LVEF, LV volumes and WMSI did not change signifi-
cantly during the follow-up, as assessed by 2D echocar-
diogram (Table 3).
Similarly, no differences were recorded between base-
line and 6 months in peak VO2 on CPET (13.3 ± 1.8 vs
14.1 ± 3.3, p = 0.37).
Clinical outcome
Patients’ clinical status was assessed according to CCS and
NYHA classes, nitrate consumption and disease-related
questionnaires at baseline and 6 and 12 months post pro-
cedure. Of importance, a significant improvement in the
CCS angina class was noted during the follow-up period
(p ≤ 0.001) in 8 out of 10 patients. In two diabetic patients,
no angina symptoms were present at accrual. In particular,
the CCS class was observed to be markedly reduced from
3.0 ± 0.5 at baseline to 1.4 ± 0.5 at 6 months (p ≤ 0.001)
and to 1.6 ± 0.5 at 12 months (p ≤ 0.001) (Fig. 4a). Notably,
the patient percentage showing a ≥ 2 class improvement
was 50% at 6 months and 37.5% at 12 months. In parallel,
the NYHA class significantly improved during the
12-month study period (n = 10, p = 0.007; Fig. 4b). More-
over, the nitrate consumption per week progressively de-
creased during the study period from 4 (2–7) to 0.25
(0.04–4) at 6 months and 0.04 (0–2) at 12 months (n = 7,
p < 0.0001), with a significant difference in nitrate
consumption at 12 months with respect to baseline
(p ≤ 0.001).
In line with these results, quality-of-life perception
suggested trends toward symptomatic benefit. The SF-12
survey showed an improvement of the PCS throughout
the follow-up period (p = 0.02) with a significant differ-
ence in the PCS at 12 months with respect to baseline
(p ≤ 0.05). Both SF-12 MCS and MLHFQ total score did
not change significantly during the follow-up period
(Table 4).
Table 2 ATMP-CD133 production and delivery
Parameter Value
BM harvest (ml) 349 ± 57
ATMP-CD133 production
Cellularity (× 106) 6.57 ± 3.45
Purity (%) 88.77 (86.30–90.75)
Vitality (%) 99.90 (99.85–99.95)
ATMP-CD133 delivery
Number of injections 12 (11–12)
Procedural duration (min) 252 ± 91
Mapping and injection time (min) 105 ± 29
Fluoroscopy time (min) 63 ± 22
Data presented as mean ± standard deviation or median (interquartile range),
as appropriate
ATMP advanced therapy medicinal product, BM bone marrow
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ATMP-CD133 functional profile
ATMP-CD133 samples were obtained in all patients.
ATMP-CD133 CPDL derived after three expansion pas-
sages varied highly among samples, ranging from 1.45 to
5.59 with a mean value of 3.32 ± 1.33. After a condi-
tioned period of 48 h, ATMP-CD133 supernatants
showed the modulation of the expression levels of sev-
eral proangiogenic, proinflammatory and anti-angiogenic
factors (Fig. 5). Among those tested, a large amount of
proangiogenic cytokines and growth factors such as IL-8
and VEGF (1722 ± 1218 and 1293 ± 1153 pg/ml/105
cells, respectively) and, in less proportion, proinflamma-
tory cytokines such as MCP-1 (768 ± 619 pg/ml/105
cells) were secreted. Consistently, low levels of
anti-angiogenic cytokines, like LIF and IL-10, were
found (13.61 ± 37.42 and 6.61 ± 10.42 pg/ml/105 cells,
respectively).
Flow cytometry analysis at 7 days showed the expres-
sion at high levels of early endothelial markers such as
CD31 (35.95 ± 16.55%) and, to a lesser extent, KDR
(26.42 ± 28.13%). The expression of CD144, recognized
as a terminally differentiated endothelial marker, was de-
tectable in a minority of cells (15.58 ± 18.01%). After
14 days, CD31 and KDR expression levels decreased to
17.95 ± 18.96% and 19.71 ± 18.32%, respectively, while
CD144 expression was maintained (14.04 ± 15.99%).
After 14 days under differentiation conditions, it was
found that ATMP-CD133 form a number of CFU-EC
which was strongly different among samples, ranging
from 47 to 700 colonies/105 cells with a median of 150
(85–415). At immunofluorescence, both clustered and
nonclustered cells derived from ATMP-CD133 were
double-positive for Ac-LDL-Dil and UEA-1 lectin stain-
ing, confirming their endothelial commitment (Fig. 6a–e).
Correlation of ATMP-CD133 secretome with perfusion
To evaluate whether the ATMP-CD133 functional profile
correlates with the observed improvements in myocardial
perfusion at SPECT, linear regression analyses were per-
formed. Notably, SSS changes were found to be significantly
correlated with the secreted proangiogenic growth factors
HGF (r= 0.80, p= 0.009) and PDGF-bb (r= 0.77, p= 0.01;
Fig. 7a, b). On the contrary, a negative significant correlation
with SSS improvements was found for the proinflammatory
cytokines RANTES (r=− 0.79, p= 0.01) and IL-6 (r=− 0.76,
p= 0.02), as shown in Fig. 7c, d. No other correlations
Table 3 Echocardiographic findings at baseline and after 6 and
12 months
Parameter Baseline 6 months 12 months p value
LVEF (%) 41.1 ± 9.5 40.9 ± 11.0 39.5 ± 10.7 0.76
LVESV (ml) 93.4 ± 38.5 92.1 ± 36.6 96.3 ± 40.1 0.78
LVEDV (ml) 153.5 ± 45.0 152.1 ± 33.7 154.2 ± 36.9 0.96
WMSI 1.8 ± 0.5 1.8 ± 0.5 1.9 ± 0.5 0.43
Data presented as mean ± standard deviation
LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic
volume, LVEDV left ventricular end-diastolic volume, WMSI wall motion
score index
A B
C D
Fig. 3 Myocardial perfusion at SPECT after 6-month follow-up. Changes of a summed stress score, b summed rest score, c summed difference
score and d number of segments with inducible ischemia per patient. Square data markers with error bars represent mean ± SD of each SPECT
parameter at baseline and 6 months (n = 9). *p≤ 0.05, **p≤ 0.01, ns = not significant
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have been detected between myocardial perfusion changes
and ATMP-CD133 functional profile.
Discussion
The RECARDIO phase I trial was designed to evalu-
ate safety and preliminary efficacy of transcatheter
intramyocardial injections of ATMP-CD133 in pa-
tients with RA and LV dysfunction (EF ≤ 45%). The
major finding of this pilot study was that LV dysfunc-
tion in highly symptomatic RA patients does not alter
the positive safety profile of catheter-based intramyo-
cardial cell delivery. Further, a favorable preliminary
efficacy signal in terms of SSS and SDS improvements
at SPECT between baseline and 6-month follow-up
was observed. Finally, a correlation was found for the
first time in the RA context between myocardial per-
fusion changes and the ATMP-CD133 secretome
profile.
Refractory angina is a debilitating condition represent-
ing an emerging burden for health systems [2]. A recent
Ontario-based study conservatively estimated the annu-
alized cost of angina-related disability including direct,
indirect and system costs at $19,209 per patient/year [1].
In this scenario, the only pharmacological therapy that
has been approved for RA in the last 40 years is the late
sodium current blocker ranolazine, whose effectiveness
has, however, been recently questioned [25].
Of importance, CT by means of catheter-based intra-
myocardial cell delivery has emerged as a viable and
promising therapy. Different BM or PB-derived autolo-
gous vasculogenic cell populations, including unfrac-
tioned mononuclear cells [26, 27] and positively selected
CD34 [28] or CD133 [29, 30] cells, have been injected
into ischemic areas to ameliorate perfusion of LV terri-
tories not otherwise amenable to revascularization. Large
meta-analyses have concordantly suggested that CT has
an overall favorable effect in symptom relief and exercise
capacity improvement in “no option” patients with RA
[12, 31, 32]. Moreover, a decreased incidence of MACE
and arrhythmias in cell-treated patients has been ob-
served [12]. Of note, the transcatheter intramyocardial
approach appears to compare favorably to intracoronary
infusion in patients with ischemic cardiomyopathy and
A B
Fig. 4 Canadian Cardiovascular Society and New York Heart Association classes over 12-month follow-up. a Canadian Cardiovascular Society (CCS) class
changes from 6 and 12 months to baseline (n= 8). b New York Heart Association (NYHA) class changes from 6 and 12 months to baseline (n= 10). Data
presented as mean ± SD. **p≤ 0.01, ***p≤ 0.001. §§§p≤ 0.001 vs baseline
Table 4 Patients’ quality of life and health status
Parameter Baseline 6 months 12 months p value
SF-12
PCS 38.4 ± 4.6 44.0 ± 6.7 44.4 ± 6.0* 0.02
MCS 49.8 ± 9.9 49.5 ± 13.2 49.2 ± 15.2 0.99
MLHFQ 35.9 ± 12.2 27.1 ± 10.7 33.1 ± 18.6 0.29
Data presented as mean ± standard deviation
SF-12, Short Form-12, PCS Physical Component Summary, MCS Mental
Component Summary, MLHFQ Minnesota Living with Heart
Failure Questionnaire
*p ≤ 0.05 vs baseline
Fig. 5 Selected secreted signature of ATMP-CD133. Pro-angiogenic
(green bars), pro-inflammatory (orange bars) and anti-angiogenic (red
bars) factor expression levels detected in supernatants of ATMP-CD133 (n
= 10). PDGF-bb platelet derived-growth factor type bb, GRO-α growth-
regulated oncogene alpha, SCF stem cell factor, HGF hepatocyte growth
factor, VEGF vascular endothelial growth factor, IL interleukin, RANTES
regulated on activation normal T cell expressed and secreted, MIP-1b
macrophage inflammatory protein-1 beta, MCP-1 monocyte
chemoattractant protein-1, LIF leukemia inhibitory factor
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LV dysfunction [33]. Very recently, a large patient-level
pooled analysis of RCT including 304 RA patients [13]
has demonstrated consistent and durable improvements
in exercise capacity, angina frequency and mortality after
intramyocardial injection of autologous CD34+ cells.
We and others have described CD133+ cells as an im-
mature population of endothelial progenitors highly
overlapping with CD34+ cells and having enhanced
paracrine-driven proangiogenic effects [16, 34–36]. In
2015, we were the first to report the full-GMP compliant
validation of BM-derived human CD133+ cells to be
used as an ATMP for cardiac CT [17] in compliance
with the European Medicine Agency (EMA) guidelines
[37] and the Committee of Advance Therapies (CAT)
recommendations [38].
In the PROGENITOR trial (Selected CD133+ Progeni-
tor Cells to Promote Angiogenesis in Patients With
Refractory Angina) [29], Jimenez-Quevedo et al. were
the first to attempt NOGA-guided endocavitary intra-
myocardial injection of CD133+ cells mobilized from PB
A B C
D E
Fig. 6 ATMP-CD133 in vitro endothelial differentiation. Representative immunofluorescence of a clustered and (b–e) not clustered CFU-EC
derived from ATMP-CD133 after 14 days in culture. Arrows indicate ATMP-CD133 committed to endothelial lineage, double-positive for
Ac-LDL-Dil (red) and UEA-1 lectin (green). UEA-1 Ulex europaeus agglutinin-1, Ac-LDL-Dil acetylated low-density lipoprotein labeled with
dioctadecyl-tetramethylindocarbocyanine perchlorate
A B
C D
Fig. 7 Correlation between ATMP-CD133 secreted factors and myocardial perfusion changes at SPECT. SSS improvements correlate (a, b) positively
with measured levels of proangiogenic factors and (c, d) negatively with proinflammatory factors (n = 9). SSS summed stress score, HGF hepatocyte
growth factor, PDGF-bb platelet derived-growth factor type bb, RANTES regulated on activation normal T cell expressed and secreted, IL interleukin
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in RA patients. Although differences between treated and
control groups were not detectable, authors were able to
show a significant improvement in CCS class and in the
number of angina episodes per month in the treatment
arm only. Besides, at 6 months, the summed score im-
proved significantly at rest and stress in the cell arm. On
the contrary, in the more recent placebo-controlled
REGENT-VSEL study (Transendocardial Delivery of Bone
Marrow–Derived CD133+ Cells on Left Ventricle Perfu-
sion and Function in Patients With Refractory Angina)
[30], Wojakowski et al. did not report any significant
reduction of myocardial ischemia and angina vs placebo
after NOGA-guided CD133+ cell intramyocardial injec-
tion, although a mild but significant reduction of LV
end-systolic and end-diastolic volumes was observed in
the cell group only. Moreover, the odds ratio adjusted for
confounding factors showed a 3.5-fold higher positive re-
sponse at SPECT in patients allocated to the active arm vs
placebo. In our RECARDIO pilot trial, the main efficacy
signal was a significant intragroup improvement in perfu-
sion at SPECT in terms of the SSS and SDS along with a
reduction in the number of segments showing inducible
myocardial ischemia after 6 months. Moreover, a consist-
ent amelioration in the CCS and NYHA classes was also
appreciated during the 12-month follow-up period.
Several differences have to be taken into account when
interpreting such mixed results. Although both the
PROGENITOR and REGENT-VSEL trials randomized
RA patients vs controls/placebo, whereas the RECAR-
DIO trial did not, these studies were underpowered to
detect perfusion differences. However, additional vari-
ables may also play a major role. One of the most rele-
vant is probably the level of the ischemic burden.
Rodrigo et al. [39] identified the large number of myo-
cardial segments at baseline as an independent predictor
of a significant improvement in perfusion, and
Wojakowski et al. [30] recognized that the inclusion of
patients with a low number of baseline ischemic seg-
ments might have influenced their results (3.6 ± 2.7 in
the REGENT-VSEL trial vs 7.3 ± 2.2 in the RECARDIO
trial). Along the same line, it is likely that the higher an-
gina class, the better the likelihood of improvement, as
reflected by the nearly identical and significant 6-month
reduction of CCS class that the RECARDIO and PRO-
GENITOR studies have observed, having included
patients with mean CCS ≥ 3 at baseline. It is worth men-
tioning that our findings of a remarkable sustained
angina benefit are perfectly in line with a consistent
body of previous RCT and meta-analyses confirming
clinical efficacy of BM or PB intramyocardial progenitor
cell injection in RA patients [13, 40, 41]. One can expect
that perfusion and symptom changes may correlate with
LV and patients’ functional amelioration. However, this
correlation was not evenly observed in previous studies
[42, 43], probably reflecting the heterogeneous nature of
this patient population.
Other factors, including guidance of cell delivery and
the number of injected cells, may also be taken into ac-
count to explain variability among studies. Different
from the REGENT-VSEL and PROGENITOR studies, in
the RECARDIO trial intramyocardial injection was fluor-
oscopy based rather than NOGA based. Given the diffi-
culty of anatomical matching between injections and
SPECT target areas [30], the fluoroscopy-based approach
may be postulated as less accurate in targeting injections
in viable ischemic areas. This limitation was partially
overcome by using electroanatomical mapping to reveal
the electrical properties within the area of interest and
exclude segments of scar. Besides, the routine use of ICE
contributed to monitoring the needle engagement into
the myocardial wall [19]. Overall, in our experience, the
fluoroscopy-based approach has confirmed feasibility,
safety and practicality as previously reported in larger
studies [44, 45]. Moreover, the unique design of the Hel-
ical Infusion Catheter has been recently proved to pro-
vide a cell retention 3-fold higher than a straight needle
approach [46].
As for the cell number, even if no dose-finding studies
are available for CD133+ cells in RA, we have delivered
into the myocardium a mean of 6.5 × 106 CD133+ cells,
a cell dosage 2-fold higher than the REGENT-VSEL
study, which is the only one of the RCT in RA delivering
selected CD133+ cells obtained from the BM.
Safety aspects
The specificity of our study with respect to previous
ones in RA was the inclusion of patients with moder-
ate to severe LV dysfunction (baseline EF 38.3%), a
scenario that may worsen the safety of CT. Neverthe-
less, we have confirmed the excellent safety profile of
catheter-based intramyocardial cell injection, including
the absence of any treatment-emergent SAE. Our
results are in line with those reported in the
FOCUS-CCTRN trial in which 92 patients with
chronic ischemic cardiomyopathy were randomized to
transendocardial cell vs placebo injection, without
safety issues in terms of mortality and SAE at early
and mid-term [47]. In particular, in our study, ILR
continuous monitoring confirmed the absence up to
12 months of malignant arrhythmias. Since one of the
major safety concerns of transendocardial cell delivery
is cardiac tamponade due to perforation, we have
routinely utilized ICE to check the real-time status of
the pericardium during injections. Such an adjuvant
imaging technique was not previously reported in CT
studies. Moreover, the long steerable shuttle sheet
(Morph) of the Helix delivery technology (BioCardia
Inc.) is helpful for safely handling the injection
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catheter both in the case of peripheral vessel tortuosity
and for crossing the aortic valve in the case of calcified
cusps.
Correlations between perfusion and ATMP-CD133
secretome
In the global position paper of the TACTICS group [48],
a recommendation has been made to incorporate CT
mechanistic endpoints into newly designed clinical trials
to corroborate unanswered hypotheses on the MoA.
Since a consistent body of evidence suggests paracrine
activity of angiogenic cells as the principal MoA [49],
there is the need to investigate the link between cell
potency and function for ATMP-CD133. To our know-
ledge, no such previous information is available in the
RA context. Our findings correlate for the first time the
ATMP-CD133 secretome profile with SSS changes, a
recognized perfusion index impacting cardiac prognosis
[50]. Specifically, a positive correlation with SSS im-
provements was found with the proangiogenic growth
factors HGF and PDGF-bb, whereas the proinflamma-
tory cytokines RANTES and IL-6 correlate negatively.
Interestingly, cardiotrophic growth factors, such as HGF
and PDGF-bb, have been consistently described as the
main components of the paracrine MoA of BM-derived
endothelial progenitors concurring to cooperative neo-
vasculogenesis and exerting chemoattractants as well as
stimulatory effects on endothelial and muscle cell
growth [51–54]. Conversely and notably, RANTES has
been described as a marker of refractory symptoms in
plasma of patients with unstable angina [55]. Moreover,
proinflammatory chemokines, as IL-6 and RANTES,
have been shown to play detrimental inflammatory dir-
ect effects on the myocardium [49] as well as to impair
survival and differentiation of transplanted endothelial
progenitors in the ischemic heart substrate [56]. In our
study, we found no correlation with other well-known
cytokines related to angiogenesis and inflammation, such
as VEGF, and neither we were able to dissect the exact
contribution of proinflammatory and anti-inflammatory
factors (i.e., IL-6 or MCP-1) to produce the angiogenic
effect. Further analyses are required on a larger sample
size for a comprehensive assessment of the biological
background of cell potency. Nevertheless, we can specu-
late that our data support the rationale for linking up a
cell-specific secretion signature with a potential thera-
peutic benefit.
Study limitations
The RECARDIO trial is a phase I uncontrolled study, so
no efficacy claims can be extrapolated. Perfusion im-
provements detected at SPECT must be confirmed by
larger RCT. Another possible study limitation is that the
ATMP-CD133 cytokine profile has been gathered from
in vitro experiments, which may not fully mimic the in
vivo environment. Moreover, correlations observed be-
tween cell secretome and SSS improvement have to be
only considered as a proof of concept of a possible
ATMP-CD133 MoA that needs further mechanistic
investigations.
Conclusions
The RECARDIO trial was the first designed to address
safety and preliminary efficacy of intramyocardial injec-
tion of ATMP-CD133 in the RA patient subset with LV
dysfunction, and to correlate perfusion changes with
CD133+ cell function. The satisfactory safety profile
along with perfusion amelioration at SPECT may open
larger controlled investigations in this context. More-
over, the observed link between cell function and SPECT
changes hints for the first time in patients at mechanistic
insights for a vasculogenic CD133+ cell MoA.
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